Cargando…

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial

BACKGROUND: Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been fully understood, and whether empagliflozin can be safely a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fortin, Elena, Lundin, Magnus, Mellbin, Linda, Norhammar, Anna, Näsman, Per, Smetana, Stina, Sörensson, Peder, Ferrannini, Ele, Rydén, Lars, Ferrannini, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422806/ https://www.ncbi.nlm.nih.gov/pubmed/37568149 http://dx.doi.org/10.1186/s12933-023-01950-0

Ejemplares similares

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study
por: Fortin, Elena, et al.
Publicado: (2022)

Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?
por: Ferrannini, Giulia, et al.
Publicado: (2020)

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
por: Ferrannini, Giulia, et al.
Publicado: (2021)

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort
por: Meziani, Sara, et al.
Publicado: (2022)

Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction
por: Wang, Anne, et al.
Publicado: (2021)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes
por: Seghieri, Marta, et al.
Publicado: (2018)

Impact of Different Bariatric Surgical Procedures on Insulin Action and β-Cell Function in Type 2 Diabetes
por: Ferrannini, Ele, et al.
Publicado: (2009)

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Response to Comment on: Ferrannini. Learning From Glycosuria. Diabetes 2011;60:695–696
por: Ferrannini, Ele
Publicado: (2011)

Learning From Glycosuria
por: Ferrannini, Ele
Publicado: (2011)

A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture
por: Ferrannini, Ele
Publicado: (2021)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
por: Ferrannini, Giulia, et al.
Publicado: (2023)

Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
por: Katsiki, Niki, et al.
Publicado: (2020)

Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
por: Ferrannini, Ele, et al.
Publicado: (2021)

Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review
por: Camastra, Stefania, et al.
Publicado: (2022)

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
por: Ferrannini, Ele, et al.
Publicado: (2021)

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
por: Haeusler, Rebecca A., et al.
Publicado: (2013)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin
por: Fonseca, Vivian, et al.
Publicado: (2009)

Comparison of neurocognitive changes among newly diagnosed tuberculosis patients with and without dysglycaemia
por: Yorke, Ernest, et al.
Publicado: (2020)

Physical Activity and Insulin Sensitivity: The RISC Study
por: Balkau, Beverley, et al.
Publicado: (2008)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
por: Natali, Andrea, et al.
Publicado: (2021)

Influence of Hyperinsulinemia and Insulin Resistance on In Vivo β-Cell Function: Their Role in Human β-Cell Dysfunction
por: Mari, Andrea, et al.
Publicado: (2011)

Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study
por: Baldi, Simona, et al.
Publicado: (2013)

Extracellular volume MRI increases the detection of myocardial abnormalities beyond late gadolinium enhancement - initial findings
por: Lundin, Magnus, et al.
Publicado: (2012)

In patients with acute myocarditis, the difference in apparent extracellular volume fraction between affected and healthy myocardium does not differ between early and late post-contrast imaging
por: Lundin, Magnus, et al.
Publicado: (2016)

Measurement of the intracellular lifetime of water to estimate myocardial cell size is not feasible in humans using clinical contrast agent doses at 1.5T
por: Lundin, Magnus, et al.
Publicado: (2016)

Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
por: Ferrannini, Ele, et al.
Publicado: (2022)

Rethinking the syndemic of tuberculosis and dysglycaemia: a Kenyan perspective on dysglycaemia as a neglected risk factor for tuberculosis
por: Kerama, Cheryl, et al.
Publicado: (2023)

Examination of Dysglycaemia among Newly Diagnosed Tuberculosis Patients in Ghana: A Cross-Sectional Study
por: Yorke, Ernest, et al.
Publicado: (2018)

Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction
por: Sörensson, Peder, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9uq8a15msg2i32hkqj0oliplqh